Standout Papers

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastat... 2020 2026 2022 2024251
  1. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma (2020)
    Sean M. McBride, Eric J. Sherman et al. Journal of Clinical Oncology

Immediate Impact

72 standout
Sub-graph 1 of 22

Citing Papers

Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
6 intermediate papers

Works of D. Spielsinger being referenced

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
2020 Standout
A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).
2018

Author Peers

Author Last Decade Papers Cites
D. Spielsinger 88 122 261 91 11 338
A. M. Leridant 262 122 163 50 11 403
Zeming Mo 139 108 155 65 11 351
Helena Sjödin 201 106 180 23 12 377
Jahan Aghalar 79 127 262 93 9 338
Marcus Couey 78 91 281 51 16 352
Hilary S. Serracino 61 95 184 63 9 328
Chang-Chuan Pan 81 115 193 76 11 323
Stephanie Tuttle 205 76 156 19 8 321
Margueritta El Asmar 141 65 176 91 13 377
Georges F. Hatoum 97 156 144 16 16 374

All Works

Loading papers...

Rankless by CCL
2026